Thomas Lynch

Nature Reviews Drug Discovery 16, 308 (2017). doi:10.1038/nrd.2017.69 Bristol-Myers Squibb has one of the deepest immuno-oncology drug pipelines, with checkpoint inhibitors, T cell and natural killer cell agonists, and metabolic modulators of the tumour microenvironment. Despite a setback with its marketed checkpoint inhibitor nivolumab in a first-line lung cancer setting last year, there are still high hopes for these emerging therapies. In March, the company hired Thomas Lynch — former CEO of Massachusetts General Physicians Organization and Director of the Yale Cancer Center — as its new Chief Scientific Officer, tasked with overseeing the progress of this pipeline. He told Asher Mullard about his R&D priorities, the promise of genomic-based diagnostics and the need for faster development of novel cancer drugs in earlier stages of disease.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Tags: News and Analysis Source Type: research